Advertisement
Canada markets close in 4 hours 49 minutes

  • S&P/TSX

    21,870.47
    -141.25 (-0.64%)
     

  • S&P 500

    5,060.39
    -10.16 (-0.20%)
     

  • DOW

    38,357.94
    -145.75 (-0.38%)
     

  • CAD/USD

    0.7287
    -0.0033 (-0.45%)
     

  • CRUDE OIL

    82.81
    -0.55 (-0.66%)
     

  • Bitcoin CAD

    89,290.93
    -2,389.52 (-2.61%)
     

  • CMC Crypto 200

    1,407.40
    -16.70 (-1.17%)
     

  • GOLD FUTURES

    2,347.30
    +5.20 (+0.22%)
     

  • RUSSELL 2000

    1,994.09
    -8.56 (-0.43%)
     

  • 10-Yr Bond

    4.6600
    +0.0620 (+1.35%)
     

  • NASDAQ

    15,719.77
    +23.13 (+0.15%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,039.88
    -4.93 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6815
    -0.0021 (-0.31%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Newscope Announces Name Change to PharmaTher Holdings Ltd.

Newscope Capital Corporation
·1 min read

TORONTO, April 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that, further to the news release dated April 8, 2021, its common shares will commence trading through the facilities of the Canadian Securities Exchange (“CSE”) under the name of PharmaTher Holdings Ltd. at the start of trading on April 15, 2021.

The Company’s ticker symbols on both the CSE and the OTCQB® Venture Market will remain the same. The Company’s ISIN and CUSIP numbers for its common shares will change to CA71716H1082 and 71716H108, respectively.

No action is required to be taken by shareholders with respect to the name change. Outstanding share and warrant certificates are not affected by the name change and do not need to be exchanged.

About Newscope Capital Corporation

Newscope Capital Corporation is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat neuropsychiatric, neurodegenerative and pain disorders.

ADVERTISEMENT

Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn.

For more information, please contact:

Fabio Chianelli
Chief Executive Officer
Newscope Capital Corporation
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.